Denmark-based gut microbiome health startup Bactolife raised $5 million in funding from the Bill & Melinda Gates Foundation in alignment with the foundation’s charitable mission, The investment will allow the startup to develop Binding Proteins™ as a novel biologic solution to reduce the risk of gut health infections in humans and animals.
Bactolife develops Binding Proteins™ that can reduce the risk of developing gut health infections at an affordable price. With Bactolife’s technology platform and the investment made by the Bill & Melinda Gates Foundation, Binding Proteins™ can be formulated into food and feed products, making them easy to ingest.
Mads Laustsen, CEO at Bactolife™ commented “With this investment, Bactolife™ is able to boost our efforts in our technology platform, allowing us to reach our end customers faster and with affordable products that can benefit the many – thereby potentially impacting millions of people’s lives worldwide”.
Sebastian Søderberg, Deputy CEO at Bactolife™ added “We are proud of and humble for the confidence the Bill & Melinda Gates Foundation has shown us. We are pleased to have funding from both Novo Holdings and the Gates Foundation, and regard this as a strong validation of Bactolife™’s potential to improve human and animal health worldwide and make these products accessible in developed and developing countries.”
Aleks Engel, Partner, Novo Seeds, Novo Holdings said: “At Novo Holdings, we are very pleased that the Bill & Melinda Gates Foundation has decided to invest in Bactolife™ – and we see that this testifies to the immense potential of Bactolife™’s Binding Protein™ platform to circumvent and avoid antimicrobial resistance. Our shared concern for global access to effective treatments for prevalent infectious diseases makes the Bill & Melinda Gates Foundation an ideal organization to collaborate with, and we are excited for the potential impact this work will have in addressing pressing global health challenges.”
